Detalhe da pesquisa
1.
Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Clin Proteomics
; 19(1): 48, 2022 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36536316
2.
Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Clin Proteomics
; 20(1): 16, 2023 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031204
3.
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Int J Mol Sci
; 19(10)2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30332834
4.
Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Ther Drug Monit
; 37(6): 733-44, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25853922
5.
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
J Clin Invest
; 134(6)2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319732
6.
CAR T cell therapies for diffuse midline glioma.
Trends Cancer
; 9(10): 791-804, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37541803
7.
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.
Sci Signal
; 16(778): eabp9586, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36976863
8.
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Cancer Res
; : OF1-OF17, 2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195023
9.
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Cancer Res
; 2023 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145169
10.
B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
Mol Cancer Res
; 20(12): 1711-1723, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166198
11.
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
Neurooncol Adv
; 3(1): vdab169, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34988452
12.
CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen.
Pharmacogenomics
; 16(6): 601-17, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25893704
13.
Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.
Talanta
; 132: 775-84, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25476377
14.
Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients.
Clin Biochem
; 47(12): 1084-90, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24747158